ADMA Biologics Inc (ADMA)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	197,673	68,132	34,788	-3,645	-28,240	-22,827	-40,292	-47,686	-65,905	-70,322	-73,135	-78,275	-71,647	-74,406	-73,610	-74,883	-75,748	-66,901	-61,422	-54,456
Revenue (ttm)	US$ in thousands	426,454	382,809	330,245	283,177	258,216	234,293	208,108	181,890	154,079	130,481	110,072	93,998	80,944	68,517	58,112	48,069	42,220	40,301	37,248	36,021
Net profit margin		46.35%	17.80%	10.53%	-1.29%	-10.94%	-9.74%	-19.36%	-26.22%	-42.77%	-53.89%	-66.44%	-83.27%	-88.51%	-108.59%	-126.67%	-155.78%	-179.41%	-166.00%	-164.90%	-151.18%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $197,673K ÷ $426,454K
= 46.35%

The net profit margin of ADMA Biologics Inc has shown a consistent improvement over the reported periods starting from a negative figure of -151.18% as of March 31, 2020, to reach a positive figure of 46.35% as of December 31, 2024.

The company managed to turn around its profitability performance significantly, transitioning from severe losses to profitability within the analyzed timeframe. This positive trend in net profit margin indicates that ADMA Biologics Inc has been able to control its costs effectively and improve its operational efficiency, leading to higher profitability levels.

This improvement in net profit margin reflects positively on the company's ability to generate profits from its operations and indicates a healthier financial position. The consistent increase in net profit margin demonstrates the company's efforts in enhancing its overall financial performance and turning around its profitability trajectory.